ATHENEX INC (NASDAQ:ATNX) will post its quarterly earnings results before the market opens on Monday, August 14th.

Shares of ATHENEX INC (NASDAQ ATNX) opened at 14.41 on Monday. The stock’s market cap is $586.29 million. The stock has a 50 day moving average price of $16.86 and a 200-day moving average price of $16.86. ATHENEX INC has a 12-month low of $11.21 and a 12-month high of $20.79.

Separately, Deutsche Bank AG assumed coverage on shares of ATHENEX INC in a report on Monday, July 10th. They issued a “buy” rating and a $20.00 price target for the company.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/athenex-inc-atnx-scheduled-to-post-earnings-on-monday.html.

In other news, Director Song-Yi Zhang purchased 328,637 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was bought at an average price of $11.00 per share, with a total value of $3,615,007.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at $44,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Johnson Yiu Nam Lau purchased 25,200 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was purchased at an average cost of $11.00 per share, with a total value of $277,200.00. Following the acquisition, the chief executive officer now directly owns 2,722,722 shares in the company, valued at $29,949,942. The disclosure for this purchase can be found here.

ATHENEX INC Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for ATHENEX INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATHENEX INC and related companies with MarketBeat.com's FREE daily email newsletter.